Azitra to Present at BIO-Europe 2024
Azitra (NYSE American: AZTR) announces its participation at BIO-Europe 2024 in Stockholm, Sweden, scheduled for Monday, November 4, 2024, at 2:30pm CET. Travis Whitfill, Chief Operating Officer, will deliver a corporate presentation highlighting the company's pipeline progress, particularly focusing on two key developments: ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity.
The company reports significant achievements in 2024, including the first patient dosing with ATR-12 and receiving FDA Fast Track designation for ATR-04. The presentation will take place at Stockholmsmässan, with opportunities for one-on-one meetings through the BIO One-on-One Partnering system.
Azitra (NYSE American: AZTR) annuncia la sua partecipazione a BIO-Europe 2024 a Stoccolma, Svezia, programmata per lunedì 4 novembre 2024, alle 14:30 CET. Travis Whitfill, Direttore Operativo, terrà una presentazione aziendale evidenziando i progressi della pipeline dell'azienda, concentrandosi in particolare su due sviluppi chiave: ATR-12 per la sindrome di Netherton e ATR-04 per la tossicità dermica indotta da inibitori EGFR.
L'azienda riporta risultati significativi nel 2024, tra cui la prima somministrazione al paziente con ATR-12 e il conseguimento della designazione Fast Track FDA per ATR-04. La presentazione avrà luogo allo Stockholmsmässan, con opportunità di incontri individuali tramite il sistema BIO One-on-One Partnering.
Azitra (NYSE American: AZTR) anuncia su participación en BIO-Europe 2024 en Estocolmo, Suecia, programada para el lunes 4 de noviembre de 2024, a las 14:30 CET. Travis Whitfill, Director de Operaciones, realizará una presentación corporativa destacando los avances en la cartera de productos de la empresa, centrándose en dos desarrollos clave: ATR-12 para el síndrome de Netherton y ATR-04 para la toxicidad dérmica inducida por inhibidores de EGFR.
La empresa informa logros significativos en 2024, incluida la primera dosificación al paciente con ATR-12 y la obtención de la designación de Fast Track de la FDA para ATR-04. La presentación se realizará en Stockholmsmässan, con oportunidades para reuniones individuales a través del sistema BIO One-on-One Partnering.
Azitra (NYSE American: AZTR)는 2024년 11월 4일 월요일 오후 2시 30분 CET에 스웨덴 스톡홀름에서 개최되는 BIO-Europe 2024에 참여할 예정이라고 발표했습니다. Travis Whitfill COO가 회사를 대표하여 프레젠테이션을 진행하며, ATR-12가 Netherton 증후군에 대한 진행 상황과 ATR-04가 EGFR 억제제에 의한 피부 독성 치료에서의 두 가지 주요 개발에 대해 강조할 것입니다.
회사는 2024년에 ATR-12의 환자 첫 투여 및 ATR-04에 대한 FDA 패스트 트랙 지정을 포함하여 중요한 성과를 보고했습니다. 프레젠테이션은 Stockholmsmässan에서 진행되며, BIO One-on-One Partnering 시스템을 통해 개인 미팅 기회가 제공됩니다.
Azitra (NYSE American: AZTR) annonce sa participation à BIO-Europe 2024 à Stockholm, en Suède, prévue pour le lundi 4 novembre 2024, à 14h30 CET. Travis Whitfill, Directeur des opérations, présentera une allocution d'entreprise mettant en avant les avancées du pipeline de la société, en se concentrant particulièrement sur deux développements clés : ATR-12 pour le syndrome de Netherton et ATR-04 pour la toxicité dermique induite par des inhibiteurs d'EGFR.
L'entreprise rapporte des réussites significatives en 2024, notamment la première dose administrée au patient avec ATR-12 et l'obtention de la désignation Fast Track de la FDA pour ATR-04. La présentation aura lieu à Stockholmsmässan, avec des opportunités de réunions individuelles grâce au système BIO One-on-One Partnering.
Azitra (NYSE American: AZTR) gibt seine Teilnahme an BIO-Europe 2024 in Stockholm, Schweden, bekannt, die für Montag, den 4. November 2024, um 14:30 Uhr CET angesetzt ist. Travis Whitfill, Chief Operating Officer, wird eine Unternehmenspräsentation halten, in der die Fortschritte der Pipeline des Unternehmens hervorgehoben werden, insbesondere zwei wichtige Entwicklungen: ATR-12 für das Netherton-Syndrom und ATR-04 für durch EGFR-Hemmer induzierte Hauttoxizität.
Das Unternehmen berichtet von bedeutenden Erfolgen im Jahr 2024, darunter die erste Dosisverabreichung an einen Patienten mit ATR-12 und die Erteilung der FDA Fast Track-Bezeichnung für ATR-04. Die Präsentation findet im Stockholmsmässan statt, mit Möglichkeiten für persönliche Gespräche über das BIO One-on-One Partnering-System.
- None.
- None.
The corporate update will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.
Details of the presentation are as follows:
BIO-Europe – November 4-6, 2024
Format: Corporate presentation
Date/Time: Monday, November 4, 2024, 2:30pm CET (8:30am ET)
Participant: Travis Whitfill, Chief Operating Officer
Location: Room K12, Stockholmsmässan,
“I am honored to present at BIO-Europe 2024 to give a corporate update,” said Travis Whitfill, Azitra’s founder and chief operating officer. “We have made extraordinary progress in 2024, including the first patient dosed with ATR-12 in Netherton syndrome and a cleared IND and Fast Track designation from the FDA for ATR-04 for patients suffering from rash due to EGFR inhibitors. I am looking forward to providing further updates and recent developments on our programs.”
To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact staskey@azitrainc.com.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in our Form 10-Q filed with the SEC on August 12, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029294091/en/
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Source: Azitra, Inc.
FAQ
When and where will Azitra (AZTR) present at BIO-Europe 2024?
What pipeline updates will Azitra (AZTR) discuss at BIO-Europe 2024?
How can investors schedule meetings with Azitra (AZTR) at BIO-Europe 2024?
What recent milestones has Azitra (AZTR) achieved in 2024?
